For immediate release
November 4, 2010
San Diego, CA — November 4, 2010 — Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today an expansion of the executive team with the appointment of Thomas B. Broudy, Ph.D. to Chief Scientific Officer (CSO) and Richard Scuderi, M.D., Ph.D. to Medical Director.
Dr. Broudy will be responsible for scientific study design, technology evaluation, and establishment of validated service offerings in the company’s laboratory group. Prior to MRL Dr. Broudy served as Director at AltheaDx, working closely with the Business Development and R&D teams to establish successful genomic service offerings, including microarray, RT-PCR, and nucleic acid isolation. He led efforts that resulted in establishment of several partnership programs for novel biomarkers, and companion diagnostic development programs in oncology and infectious disease with biopharma companies. Dr. Broudy earned his Ph.D. from The Rockefeller University.
Dr. Scuderi currently serves as a member of Pacific Rim Pathology group with a specialty in Hematopathology. He is certified by the American Board of Pathology and by the Medical Board of California. Dr. Scuderi has authored a number of scientific papers on various hematology-oncology topics including Hodgkin and non-Hodgkin lymphoma, hemoglobinopathies, and acute lymphoblastic leukemia. Dr. Richard Scuderi received his Bachelors degree in Molecular and Cell Biology from University of California, Berkeley and his M.D., Ph.D. in hemotology with a molecular emphasis from the Karolinska Institute in Stockholm.
“I am grateful that Drs. Broudy and Scuderi have decided to join Molecular Response during this exciting period,” noted CEO, Cyrus K. Mirsaidi of Molecular Response. “They each bring a unique background and impressive skill set to MRL. I will depend on them to help build MRL into a leading company that will endeavor to improve lives through the use and development of novel molecular diagnostics.”
About Molecular Response
Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and cost of therapeutic drug development for our partners by translating clinically relevant molecular response marker data into high-value knowledge while fully integrated into existing pharmaceutical development processes and programs; Our results reduce risk and cost of drug development and allow for the most informed decisions with best chance of success to advance therapeutic programs.
For additional information please visit www.molecularresponse.com.